Table 4.
Mean change in QUARTIS scores during the first year of SLIT with five-grass pollen tablet (n = 253)
| QUARTIS domain | Range of scorea (min–max) | Q1 score (mean ± SD) before SLIT | Q2 score (mean ± SD) during SLIT | Change in score (mean ± SD) until end of SLIT | p valueb |
|---|---|---|---|---|---|
| Nasal symptoms | 4–20 | 14.0 ± 3.7 | 10.2 ± 4.1 | −3.8 ± 4.3 | <0.0001 |
| Ocular symptoms | 2–10 | 6.4 ± 2.5 | 4.4 ± 2.2 | −2.0 ± 2.8 | <0.0001 |
| Allergy in everyday life | 3–15 | 9.8 ± 3.1 | 7.3 ± 3.2 | −2.5 ± 3.6 | <0.0001 |
| Ease of SLIT intake | 2–8 | 2.5 ± 1.0 | 2.3 ± 0.7 | −0.2 ± 1.0 | 0.0067 |
| Disadvantages of SLIT | 5–25 | 8.7 ± 3.5 | 7.9 ± 2.8 | −0.8 ± 2.9 | <0.0001 |
A decrease in nasal symptoms, ocular symptoms, allergy in everyday life, ease of SLIT intake, or disadvantages of SLIT represents a favourable result
Q questionnaire, QUARTIS Questionnaire sur l’Allergie Respiratoire Traitée par Immunothérapie Sublinguale, SD standard deviation, SLIT sublingual immunotherapy
aSum of the ratings of all items in the domain
bWilcoxon test within the subgroup of patients who filled in the QUARTIS questionnaire before the start of SLIT and at least once thereafter